Jennifer Locke

2006 Research Trainee Award,

Mechanistic approaches to androgen-independent prostate cancer

Prostate cancer is the main form of cancer affecting men in the western world. Because cellular mutations within the prostate are regulated in part by androgens (male sex hormones), treatment of prostate cancer usually involves starving the prostate of androgens. While this therapy initially stops cancer progression, over time, the cancer continues to progress.

Jennifer Locke is researching why prostate cancer progresses despite the apparent lack of androgens during treatment for the disease. Jennifer is testing the hypothesis that new androgens are produced within the prostate during androgen-deprivation therapy, causing the cancer to reoccur. Using molecular and analytical techniques, she is investigating androgen synthesis pathways. This research could enable identification and evaluation of inhibitors of these pathways, which may lead to new therapeutic options. Her ultimate goal is to improve treatment outcomes and quality of life for prostate cancer patients.

Listen to Jennifer Locke's speech from the 2006 Trainee Awards Celebration (3.2 mb)

Completed award term, March 2008

Back to 2006 Research Trainee Awards

 

Research Details

Research Area
Biomedical

Partnership Award
Jointly funded with VGH & UBC Hospital Foundation

University/Institution
University of British Columbia

Research Location
Vancouver General Hospital (Vancouver Coastal Health Research Institute)

Faculty/Department
Medicine / Medicine (Experimental Medicine)

Supervisor
Dr. Colleen Nelson, Associate Professor, Medicine / Surgery and Pathology and Laboratory Medicine

Dr. Emma Guns, Assistant Professor, Medicine / Surgery